

Listing of Claims:

1. **(previously presented)** A method for statistically significantly potentiating the activity of a prodrug, the method comprising co-administering an oligonucleotide with the prodrug, wherein the oligonucleotide does not have two 5' and four 3' 2-O-methylribonucleosides and wherein the oligonucleotide does not have the sequence of SEQ ID NO: 1.
2. **(original)** The method according to claim 1, wherein the prodrug is an ester or an amide of an active compound.
3. **(currently amended)** The method according to claim 2, wherein the active compound is an anti-cancer compound drug.
4. **(original)** The method according to claim 3, wherein the anti-cancer drug is SN-38.
5. **(original)** The method according to claim 4, wherein the prodrug is Camptosar.
6. **(currently amended)** The method according to any one of claims 1-5, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.
7. **(canceled)**
8. **(previously presented)** The method according to claim 6, wherein the oligonucleotide comprises a 2'-O-substituted ribonucleoside.

9. **(currently amended)** The method according to claim 8, wherein the 2'-O-substituted ribonucleoside is selected from the group consisting of 2'-O-methyl ribonucleosides and 2'-O-methoxyethoxy ribonucleosides.
10. **(previously presented)** A method for statistically significantly potentiating the activity of a prodrug, the method comprising co-administering an oligonucleotide with the prodrug, wherein the the oligonucleotide is administered before the prodrug.
11. **(original)** The method according to claim 10, wherein the prodrug is an ester or an amide of an active compound.
12. **(original)** The method according to claim 11, wherein the active compound is an anti-cancer drug.
13. **(original)** The method according to claim 12, wherein the anti-cancer drug is SN-38.
14. **(original)** The method according to claim 13, wherein the prodrug is Camptosar.
15. **(currently amended)** The method according to any one of claims 10-14, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.
16. **(canceled)**
17. **(original)** The method according to claim 15, wherein the oligonucleotide comprises a 2'-O-substituted ribonucleoside.

18. **(currently amended)** The method according to claim 17, wherein the 2'-O-substituted ribonucleoside is selected from the group consisting of 2'-O-methyl ribonucleosides and 2'-O-methoxyethoxy ribonucleosides.
19. **(previously presented)** A method for statistically significantly potentiating the activity of a prodrug, the method comprising co-administering an oligonucleotide with the prodrug, wherein the prodrug is present in an amount that would not be therapeutically effective in the absence of the oligonucleotide.
20. **(original)** The method according to claim 19, wherein the prodrug is an ester or an amide of an active compound.
21. **(original)** The method according to claim 20, wherein the active compound is an anti-cancer drug.
22. **(original)** The method according to claim 21, wherein the anti-cancer drug is SN-38.
23. **(original)** The method according to claim 22, wherein the prodrug is Camptosar.
24. **(currently amended)** The method according to any one of claims 19-23, wherein the oligonucleotide is selected from the group consisting of oligonucleotide phosphorothioates and oligonucleotide phosphorodithioates.
25. **(canceled)**
26. **(previously presented)** The method according to claim 24, wherein the oligonucleotide comprises a 2'-O-substituted ribonucleoside.

27. **(currently amended)** The method according to claim 26, wherein the 2'-O-substituted ribonucleoside is selected from the group consisting of 2'-O-methyl ribonucleosides and 2'-O-methoxyethoxy ribonucleosides.